A study by Northwestern Medicine reveals a long noncoding RNA, PRCAT71, linked to prostate cancer progression, acting as a potential prognostic biomarker and therapeutic target. Researchers found that PRCAT71, highly expressed in metastatic and primary prostate cancer tissues, helps stabilize androgen receptor mRNA, thereby enhancing its signaling—crucial for cancer development. By targeting PRCAT71, they noted reduced growth and invasiveness of prostate cancer cells. Ongoing research will further explore PRCAT71's regulatory roles and potential in prostate and other cancers.
The findings suggest that PRCAT71 may be a potential diagnostic and prognostic biomarker and therapeutic target for patients with prostate cancer.
Using advanced RNA sequencing techniques, Cao's team discovered that lncRNA transcript 71 (PRCAT71) was highly expressed exclusively in metastatic and primary prostate cancer tissue.
The research indicates that targeting PRCAT71 significantly reduces cell proliferation, colony formation, and invasiveness of prostate cancer cells, revealing its therapeutic potential.
Our study demonstrates a coordinated regulation of androgen receptor mRNA by lncRNA PRCAT71 and RNA binding proteins, crucial for prostate cancer progression.
Collection
[
|
...
]